Solventum Corporation $SOLV Shares Purchased by Strong Tower Advisory Services

Strong Tower Advisory Services boosted its stake in Solventum Corporation (NYSE:SOLV) by 8.3% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 107,408 shares of the company’s stock after purchasing an additional 8,239 shares during the period. Solventum accounts for 1.5% of Strong Tower Advisory Services’ holdings, making the stock its 26th biggest holding. Strong Tower Advisory Services’ holdings in Solventum were worth $8,511,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently added to or reduced their stakes in SOLV. Independent Franchise Partners LLP increased its stake in shares of Solventum by 27.2% in the third quarter. Independent Franchise Partners LLP now owns 12,899,240 shares of the company’s stock valued at $941,645,000 after purchasing an additional 2,758,174 shares during the period. Boston Partners increased its stake in shares of Solventum by 26.1% in the third quarter. Boston Partners now owns 4,630,300 shares of the company’s stock valued at $338,006,000 after purchasing an additional 959,543 shares during the period. Vanguard Group Inc. increased its stake in shares of Solventum by 5.3% in the third quarter. Vanguard Group Inc. now owns 17,121,198 shares of the company’s stock valued at $1,249,847,000 after purchasing an additional 867,837 shares during the period. Balyasny Asset Management L.P. acquired a new stake in shares of Solventum in the third quarter valued at approximately $42,393,000. Finally, Pzena Investment Management LLC acquired a new stake in shares of Solventum in the third quarter valued at approximately $31,701,000.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Stifel Nicolaus raised their price target on shares of Solventum from $88.00 to $105.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. KeyCorp raised their price target on Solventum from $97.00 to $99.00 and gave the company an “overweight” rating in a report on Friday, February 27th. BTIG Research reissued a “buy” rating and set a $100.00 price target on shares of Solventum in a report on Friday, February 27th. Wall Street Zen lowered Solventum from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Finally, Mizuho set a $100.00 price target on Solventum and gave the company an “outperform” rating in a report on Tuesday, January 20th. Seven equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $90.64.

Insider Transactions at Solventum

In other news, Director Amy Mcbride Wendell bought 1,475 shares of the stock in a transaction that occurred on Tuesday, March 10th. The shares were purchased at an average cost of $68.03 per share, with a total value of $100,344.25. Following the completion of the acquisition, the director directly owned 5,039 shares in the company, valued at approximately $342,803.17. The trade was a 41.39% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.24% of the stock is currently owned by insiders.

Solventum Price Performance

NYSE SOLV opened at $65.78 on Friday. Solventum Corporation has a 12 month low of $62.38 and a 12 month high of $88.20. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.23 and a quick ratio of 0.89. The firm has a market capitalization of $11.41 billion, a PE ratio of 7.42, a P/E/G ratio of 1.08 and a beta of 0.71. The company’s 50 day simple moving average is $70.23 and its 200 day simple moving average is $74.85.

Solventum (NYSE:SOLV) last posted its quarterly earnings data on Thursday, February 26th. The company reported $1.57 EPS for the quarter, beating analysts’ consensus estimates of $1.50 by $0.07. Solventum had a net margin of 18.69% and a return on equity of 25.26%. The business had revenue of $2 billion for the quarter, compared to analyst estimates of $1.96 billion. During the same quarter last year, the business earned $1.41 earnings per share. The business’s revenue for the quarter was down 3.7% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. As a group, equities research analysts forecast that Solventum Corporation will post 6.58 EPS for the current fiscal year.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.